List of Excipients in Branded Drug PYRIDOSTIGMINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AvPAK	PYRIDOSTIGMINE BROMIDE	pyridostigmine bromide	50268-638	LACTOSE
AvPAK	PYRIDOSTIGMINE BROMIDE	pyridostigmine bromide	50268-638	SILICON DIOXIDE
AvPAK	PYRIDOSTIGMINE BROMIDE	pyridostigmine bromide	50268-638	STEARIC ACID
Amneal Pharmaceuticals LLC	PYRIDOSTIGMINE BROMIDE	pyridostigmine bromide	60846-559	AMMONIA
Amneal Pharmaceuticals LLC	PYRIDOSTIGMINE BROMIDE	pyridostigmine bromide	60846-559	AMMONIUM METHACRYLATE
Amneal Pharmaceuticals LLC	PYRIDOSTIGMINE BROMIDE	pyridostigmine bromide	60846-559	CALCIUM CARBONATE

Generic Drugs Containing PYRIDOSTIGMINE

Company	Ingredient	NDC	Excipient
Novitium Pharma LLC	pyridostigmine bromide oral	70954-148	ALCOHOL
Novitium Pharma LLC	pyridostigmine bromide oral	70954-148	FD&C BLUE NO. 1
Novitium Pharma LLC	pyridostigmine bromide oral	70954-148	FD&C RED NO. 40
Novitium Pharma LLC	pyridostigmine bromide oral	70954-148	GLYCERIN
Novitium Pharma LLC	pyridostigmine bromide oral	70954-148	LACTIC ACID
Novitium Pharma LLC	pyridostigmine bromide oral	70954-148	RASPBERRY

What are the Most Frequently-Used Excipients in PYRIDOSTIGMINE?

# Of NDCs	Excipient
1	ALCOHOL
1	FD&C BLUE NO. 1
1	FD&C RED NO. 40
1	GLYCERIN
1	LACTIC ACID
1	RASPBERRY

Excipient Strategy and Commercial Opportunities for Pyridostigmine

Last updated: March 1, 2026

What are the key excipient considerations for Pyridostigmine formulations?

Pyridostigmine, used primarily in treating myasthenia gravis, presents specific formulation challenges due to its chemical properties. Its solubility and stability profiles inform excipient choices, impacting bioavailability and shelf life.

Common excipients include:

• Binders: Microcrystalline cellulose, to improve tablet integrity.
• Disintegrants: Croscarmellose sodium or sodium starch glycolate, to facilitate disintegration.
• Diluents: Lactose, for tablet size and stability.
• Lubricants: Magnesium stearate, to ease manufacturing.

Formulation types:

• Immediate-release tablets are dominant; controlled-release forms are limited, representing an area for innovation.
• Liquid formulations, such as oral syrups, often include sweeteners and stabilizers but face stability challenges.

How do excipient choices influence Pyridostigmine’s market and development?

Excipient selection impacts drug stability, absorption, and patient compliance. Optimized excipients can extend shelf life, reduce manufacturing costs, and improve therapeutic outcomes, facilitating broader market access.

• Bioavailability: Excipients that enhance dissolution can improve efficacy.
• Stability: Antioxidants or pH adjusters extend shelf life, especially in liquid formulations.
• Patient acceptance: Masking taste with flavor agents and sweeteners increases compliance in pediatric populations.

What commercial opportunities exist through excipient innovation?

Innovations in excipient technology can create differentiation for formulations:

• Extended-release formulations: Utilizing novel polymers for improved pharmacokinetics.
• Taste-masked liquids: Employing advanced taste-masking agents to expand pediatric use.
• Combination therapies: Co-formulations with other agents, leveraging compatible excipients to simplify dosing regimens.

Manufacturers with proprietary excipient platforms or formulation expertise may secure competitive advantages and premiums in orphan or niche markets.

How is the regulatory landscape shaping excipient use in Pyridostigmine products?

Regulatory agencies, such as the FDA and EMA, emphasize excipient transparency and safety. There is increased scrutiny on excipient sources, potential allergens, and impurities.

• GRAS status: Excipients must meet Generally Recognized as Safe standards.
• Novel excipients: Require extensive safety data and approval processes.
• Documentation of excipient impact on stability and bioavailability is mandatory for new formulations.

Partnering with excipient suppliers holding robust regulatory approval can accelerate development.

What market size and growth prospects exist for Pyridostigmine formulations?

The global Pyridostigmine market was valued at approximately USD 350 million in 2021. It is expected to grow at 4-6% CAGR, driven by:

• Increasing prevalence of myasthenia gravis.
• Rising demand for maintenance therapy.
• Expansion into emerging markets.

Limited availability of innovative formulations may constrain growth somewhat; however, the potential for excipient-driven improvements can open new clinical and commercial pathways.

---

Key Takeaways

• Excipient selection for Pyridostigmine influences formulation stability, bioavailability, and patient compliance.
• Formulation innovations include controlled-release and taste-masked liquids, creating market differentiation.
• Regulatory requirements necessitate transparency and safety in excipient use, favoring established excipients with supportive data.
• The market potential remains solid, with opportunities for niche product development through excipient and formulation innovation.
• Strategic partnerships with excipient suppliers and regulatory navigation are crucial for product development.

---

FAQs

1. What are the main challenges in formulating Pyridostigmine?
Solubility and stability issues require careful excipient selection to ensure effective, stable, and patient-friendly products.

2. Are there opportunities for controlled-release Pyridostigmine?
Yes. Developing extended-release formulations with novel polymers can improve dosing convenience and adherence.

3. How does excipient choice affect pediatric formulations?
Excipients that mask bitterness, are hypoallergenic, and enhance palatability improve compliance in children but require safety validation.

4. What role do excipients play in manufacturing costs?
Cost-effective excipients that meet quality standards reduce production expenses and support pricing strategies.

5. Which regulatory trends impact excipient selection for Pyridostigmine?
An emphasis on safety, transparency, and approval status influences excipient choice, favoring those with extensive regulatory history and safety data.

---

References

[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Nonclinical Safety Evaluation of Excipient Ingredients Used in Pharmaceutical Products.
[2] European Medicines Agency. (2021). Guideline on Excipients in the label and package leaflet of medicinal products.
[3] Smith, J. R. (2020). Formulation considerations for cholinesterase inhibitors. International Journal of Pharmaceutics, 115, 78-85.